Biocompatible Coatings to

Enhance Your Medical Device

Advancements in medical devices have demanded innovative coatings to enhance the biological acceptance and reduce the challenges faced when artificial materials are in contact with the body.

BioInteractions’ Biocompatible Coatings 

BioInteractions have developed three unique polymer coatings to help with these challenges:

Astute® 

Anti-thrombogenic Coating

Triple-Endothelial Action

Astute functionalises an active component within its polymer backbone and is combined with passive components to actively prevents a thrombus from forming.


Astute® Triple Endothelial Action:

  • Actively negates platelet activation
  • Prevents protein and cellular deposition
  • Non-leaching coating to give long term efficacy

AvertPlus

Dual Active Contact Kill Mechanism

Antimicrobial Coating

AvertPlus™ reduces device related infections and targets biofilm formation. The active contact kill mechanism is paired with a passive process to reduce the presence of bacteria on the surface


AvertPlus™ Dual Active Contact Kill Mechanism:

  • Active disruption of a broad-spectrum bacteria that results in lysis
  • Prevents deposition and adhesion of proteins
  • Non-leaching coating gives long term efficacy throughout lifetime of the coating

Assist™ 

Enhanced Lubricious Activity

Hydrophilic Coating

Assist™ minimises the obstacles faced at the device-body interface. The polymer coating provides a highly hydrophilic surface which reduces friction as well as preventing protein binding and platelet deposition to improve patient well-being.


Assist™ Enhanced Lubricity:

  • Hydrophilic properties as well as prevents deposition onto the surface
  • Non-leaching, non-cytotoxic and stable coating
  • Available as UV Cured or Heat Cured

Commitment to Care Services

Our Commitment to Care Service (C2C) builds on our expertise in facing a broad range of challenges. We have combined our innovative coatings with optimised application processes and support services as a complete solution for our partners. We have discovered the impact of applying the coating on the result of the quality and efficacy of the coating. We are able to develop and optimise a coating process as well as provide the coating capabilities in our cleanroom facilities for our customers.


We have extended our C2C services to include testing methods to highlight the benefits of using our coating technology. This can be used to help support regulatory submissions. We have expertise in helping our partners through the submission process helping to reduce significant challenges during this process

Our in-depth understanding of the range of challenges faced by materials, provides us with an exclusive advantage to help our partners. Our coating technologies provide innovative advantages to the device and helps to Assist™ in improving patient well-being.

Back To Top 

Go to article: Home | When Treatments Turn ToxicGo to article: In This Issue Go to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: ContentsGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: NewsGo to article: Tricor SystemsGo to article: The Medical Industry BriefingGo to article: RPMC Lasers Go to article: Health screening: the need for a more proactive approachGo to article: Mi3 Medical IntelligenceGo to article: Can AI make healthcare more human?Go to article: Swisstec 3DGo to article: Combining virtual reality and touch for surgical training Go to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: A nose for trouble: the bio-sensor aiming to sniff out diseaseGo to article: PI Ceramic Company Insight Go to article: PI CeramicGo to article: Elcam MedicalGo to article: Empowerment vs deceit: the darker side of digital health communitiesGo to article: Sandvik Company InsightGo to article: Sandvik Go to article: What’s the solution to the ethylene oxide crisis?Go to article: General PlasticsGo to article: Ocean Insight Company InsightGo to article: Ocean InsightGo to article: SanminaGo to article:  Q&A: talking clinical trial tech and acquisitions with MedidataGo to article: Caeleste Company Insight Go to article: CaelesteGo to article: Not very re-Essureing: how a contraceptive implant can ruin livesGo to article: Apple RubberGo to article: axxosGo to article: Lessons and leftover challenges from MDR preparationsGo to article: maxonGo to article: micrometal Go to article: Role of wearable sensors in the early diagnosis of Graft Versus Host DiseaseGo to article: MedtecLIVEGo to article: Predicting influenza outbreak using Fitbit wearable technologyGo to article: Schurter Go to article: ESMAGo to article: AccumoldGo to article: Potential use of light-degradable medical devices in gastrointestinal proceduresGo to article: Smiths InterconnectGo to article: Hernia meshes allegedly used without clinical evidenceGo to article: MPS Microsystems Company InsightGo to article: MPS MicrosystemsGo to article: JenaValve advances TAVR programme with FDA breakthrough device designationGo to article: Deals in brief powered by GlobaldataGo to article: Micro Systems TechnologiesGo to article: The key list powered by GlobaldataGo to article: Abatek InternationalGo to article: EventsGo to article: Next Issue